Get the app
USHealthcare

Becton Dickinson and Company (BDX)

US · Healthcare · Medical Instruments & Supplies

$181.38-0.26%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$4.98B
Revenue YoY
-9.5%
Net profit
$377.0M
Profit YoY
-34.3%
EPS
$3.23
EPS estimate
$3.14
Net margin
7.6%

EPS came in at 3.23 against a street estimate of 3.14 — a beat of 2.9%.

Key statistics

Market cap
$49.53B
P/E
31.5
Forward P/E
14.0
P/B
2.07
Book value
$89.64
EPS (TTM)
$5.78
Dividend yield
2.25%
52-week high
$191.94
52-week low
$124.47
50-day MA
$173.57
200-day MA
$160.83
Beta
0.28

Analyst view

Analysts rate Becton Dickinson and Company a buy (7 buy, 9 hold, 0 sell out of 16) with an average price target of $195.67.

From the latest earnings call · 2026-08-06

CONFIDENT BD delivered Q3 FY26 revenue of $5B (+4.4%), adjusted EPS of $3.23 (+4.9%), ahead of expectations. Growth platforms (biologics, APM, PureWick, tissue regeneration) driving momentum. Raised FY26 EPS guidance midpoint. Alaris and China headwinds playing out as expected. Q3 FY26 U.S. driving strength in MDS, specimen management, APM. China headwinds concentrated in vaccines (stabilizing) and general market dynamics; expected to shrink to 3-4% of NBD revenue. Analysts probed sustainability of Q3 strength, competitive share gains, and Q4 deceleration. Management emphasized growth platforms are structural (not onetime), commercial changes embedded, and Alaris decline is the primary Q4/FY27 headwind—fully expected and offset by pricing/productivity. 2026-08-06…

Full summary in the app.

Shareholding

Insiders
0.43%
Institutions
99.72%

Largest institutional holders

FundStake
Arnhold & S. Bleichroeder Advisers, LLC10.14%
BlackRock Inc9.60%
Vanguard Capital Management, LLC6.79%
Vanguard Portfolio Management, LLC5.62%
State Street Corp5.07%
Amvescap Plc.3.74%
T. Rowe Price Investment Management,Inc.3.56%
Massachusetts Financial Services Company3.34%

Recent filings & reports

DocumentDate
Quarterly report · Q3 FY2026
BECTON, DICKINSON AND COMPANY Form 10-Q for Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Q3 2026 Revenue: $4,983 million (vs. $4,726 million
2026-08-06
Results announced · Q4 FY2026
BD (BECTON, DICKINSON AND COMPANY) - Q3 FISCAL 2026 SUMMARY HEADLINE NUMBERS • Q3 Revenue: $4,983 million, up 5.4% as reported (4.4% currency-neutra
2026-08-06
Board / officer change · Q4 FY2026
BECTON, DICKINSON AND COMPANY (BDX) - 8-K FILING SUMMARY Date: July 19-22, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Michael D. Garrison, Executive
2026-07-22
Reg FD disclosure · Q3 FY2026
BECTON, DICKINSON AND COMPANY (BDX) – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • BD resumed U.S. shipments of ChloraPrep™ (antiseptic skin pre
2026-05-29
Material agreement · Q3 FY2026
BECTON, DICKINSON AND COMPANY (BDX) – FORM 8-K SUMMARY HEADLINE NUMBERS • BD's Luxembourg subsidiary (Becton Dickinson Euro Finance S.à r.l.) issued
2026-05-20
Quarterly report · Q2 FY2026
BECTON, DICKINSON AND COMPANY — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenues (Q2 2026): $4,714 million, up 5.2% from $4,480 million (Q2 2025) •
2026-05-07
Quarterly report · Q1 FY2026
BECTON, DICKINSON AND COMPANY (BDX) - Q1 FY2026 10-Q SUMMARY HEADLINE NUMBERS • Revenues (Q1 FY2026): $5,252 million vs. $5,168 million prior year (
2026-02-09
Proxy statement · Q1 FY2026
BECTON, DICKINSON AND COMPANY (BD) — PROXY STATEMENT SUMMARY CEO TOTAL COMPENSATION & CHANGE • CEO Tom Polen's 2025 total direct compensation compri
2025-12-18

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$1.05 / share
ex-date Sep 9, 2026 · pay Sep 30, 2026
2026-09-09
Dividend$1.05 / share
ex-date Jun 9, 2026 · pay Jun 30, 2026
2026-06-09
Dividend$1.05 / share
ex-date Mar 10, 2026 · pay Mar 31, 2026
2026-03-10
Split1272 : 1000
effective Feb 10, 2026
2026-02-10
Dividend$0.83 / share
ex-date Dec 8, 2025 · pay Dec 31, 2025
2025-12-08
Dividend$0.82 / share
ex-date Sep 8, 2025 · pay Sep 30, 2025
2025-09-08

Deals & corporate news

AnnouncementDate
Company to repurchase $2B shares and repay $2B debt from spinoff proceeds
Becton, Dickinson and Company (BD) completed a spin-off transaction on February 6, 2026, separating a business unit into SpinCo. As part of this separation, BD received a $4 billion cash dis
2026-02-09
Announced reverse morris trust combination with Waters Corporation
Becton, Dickinson and Company (BD) filed paperwork related to its planned spinoff of its Biosciences and Diagnostic Solutions business through a Reverse Morris Trust (RMT) transaction with W
2026-02-05

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Becton Dickinson and Company — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.